AbbVie
ABBV
$136.86
Share price
-0.01%
Change (1 day)
-6.60%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
AbbVie (ABBV) - Total debt
Total debt on the balance sheet as of December 2022 : $63.27 B
According to AbbVie's latest financial reports the company's total debt is $63.27 B. A company’s total debt is the sum of all current and non-current debts.
AbbVie - Total debt on balance sheet (from 2012 to 2022)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2022-12-31 | $63.27 B | -17.49% |
| 2021-12-31 | $76.68 B | -10.89% |
| 2020-12-31 | $86.05 B | 28.97% |
| 2019-12-31 | $66.72 B | 65.54% |
| 2018-12-31 | $40.31 B | 7.87% |
| 2017-12-31 | $37.36 B | 1.43% |
| 2016-12-31 | $36.84 B | 16.33% |
| 2015-12-31 | $31.67 B | 110.99% |
| 2014-12-31 | $15.01 B | 1.96% |
| 2013-12-31 | $14.72 B | -6.06% |
| 2012-12-31 | $15.67 B |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $34.87 B | -44.89% | 🇺🇸 USA |
 Eli Lilly LLY | $18.88 B | -70.15% | 🇺🇸 USA |
 Amgen AMGN | $61.59 B | -2.65% | 🇺🇸 USA |
 Biogen BIIB | $6.60 B | -89.55% | 🇺🇸 USA |
 Gilead Sciences GILD | $25.23 B | -60.11% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $39.37 B | -37.77% | 🇺🇸 USA |
 AstraZeneca AZN | $31.50 B | -50.21% | 🇬🇧 UK |
 GlaxoSmithKline GSK | $25.89 B | -59.07% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | $0.25 B | -99.59% | 🇺🇸 USA |